VPRO — Viropro Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $11.93m
- $0.57m
Annual income statement for Viropro, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2007 November 30th | 2008 November 30th | 2009 November 30th | 2010 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0.264 | 0 | 0 | 0.571 |
Cost of Revenue | ||||
Gross Profit | 0.264 | 0 | 0 | — |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 2.04 | 1.25 | 1.08 | 1.57 |
Operating Profit | -1.78 | -1.25 | -1.08 | -0.997 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -2.65 | -1.74 | -1.46 | -1.01 |
Provision for Income Taxes | ||||
Net Income After Taxes | -2.65 | -1.74 | -1.46 | -1.01 |
Net Income Before Extraordinary Items | ||||
Net Income | -2.65 | -1.74 | -1.46 | -1.01 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Dilution Adjustment | ||||
Diluted Net Income | -2.65 | -1.74 | -1.46 | -1.01 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.075 | -0.036 | -0.012 | -0.004 |
Dividends per Share |